Key result
Persistence with four-drug antihypertensive therapy is linked to ~12% fewer non-fatal CV events.
Why the study?
Real-world data on adherence, persistence, and cardiovascular outcomes in patients receiving four-drug antihypertensive therapy were limited.
Does lower pill burden improve adherence and persistence, and does persistence reduce cardiovascular events and mortality in patients receiving four-drug antihypertensive therapy?
Cohort (n=228,594)
Yes
Does lower pill burden improve adherence and persistence, and does persistence reduce cardiovascular events and mortality in patients receiving four-drug antihypertensive therapy?
In patients on four-drug antihypertensive therapy, reducing pill burden improves adherence and persistence, which is associated with significantly lower risks of cardiovascular events and mortality.
Answers are grounded in this paper and cite their sources.
Observational four-drug antihypertensive data should not change practice; leaves open optimal regimens and CVE associations in resistant hypertension.
AIMS: Describe real-world use, adherence, persistence, and risk of non-fatal cardiovascular events (CVE) and mortality among patients receiving four-drug antihypertensive therapy. METHODS AND RESULTS: This was a retrospective, longitudinal cohort study of Italian administrative healthcare databases (N=7,160,298). Eligible patients were ≥18 years and received four-drug therapy between 2018 and 2022. Class- and molecule-level subcohort analyses required data for ≥1 year either side of four-drug therapy identification. Adherence and persistence were based on prescription availability. A Cox proportional hazards model was used for risk assessment.Among 228,594 eligible patients, 113,755 received either an angiotensin-converting enzyme inhibitor (ACEi; n=57,473) or angiotensin II receptor blocker (n=56,282), thiazide/thiazide-like diuretic (DIU), calcium channel blocker (CCB), and a fourth class (mostly beta-blockers [BBs]; n=87,022).In the Class subcohort (ACEi+DIU+CCB+BB; n=41,903), high adherence was more frequent among patients receiving two (52.1%) versus three (40.2%) or four (25.0%) pills (global P<0.001); persistence was also improved (P<0.02 from 6 months). Adherence and persistence were significantly higher with two versus three pills in the Molecule subcohort (perindopril, indapamide, amlodipine, and bisoprolol; n=8007). For persistent versus non-persistent patients, there was a risk reduction for CVE (12.4%; P<0.001) and mortality (16.4%; P<0.001) in the Class subcohort, with similar findings in the Molecule subcohort (20.9% [P=0.003] and 20.9% [P=0.002], respectively). CONCLUSION: In patients receiving four-drug antihypertensive therapy, adherence and persistence were significantly improved with lower pill burden. Persistence was associated with lower risks of CVE and mortality.
No takes yet. Share an insight, caveat, or question.
Mancia et al. (2026) conducted a cohort in Hypertension (n=228,594). Persistence to four-drug antihypertensive therapy vs. Non-persistence was evaluated on Non-fatal cardiovascular events (CVE) (12.4% risk reduction, p=<0.001). Persistence to four-drug antihypertensive therapy was associated with a 12.4% risk reduction for non-fatal cardiovascular events and 16.4% for mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: